SCHEMBL13103441

SCHEMBL13103441

COc1cc2[nH]cc(-c3cc4cccnc4n3S(=O)(=O)c3ccc(C)cc3)c2nc1OC

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.42
TSHR P16473 2/20 0.37
CCNE1 P24864 2/20 0.36
CDK2 P24941 2/20 0.36
PTGDR2 Q9Y5Y4 5/20 0.36
LMNA P02545 3/20 0.36
MAPT P10636 3/20 0.36
TDP1 Q9NUW8 3/20 0.36
KMT2A Q03164 3/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
MEN1 O00255 2/20 0.36
AGTR1 P30556 2/20 0.36
NPSR1 Q6W5P4 2/20 0.36
TP53 P04637 1/20 0.36
HPGD P15428 1/20 0.36
CXCR2 P25025 1/20 0.36
ALDH1A1 P00352 2/20 0.35
HTT P42858 2/20 0.35
KDM4E B2RXH2 1/20 0.35
ENPP3 O14638 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1748508 0.86 L3MBTL1 (0.44) L3MBTL1TSHRCCNE1CDK2PTGDR2
SCHEMBL2988252 0.86 LMNA (0.34) TSHRPTGDR2LMNAMAPTKMT2A
SCHEMBL2987041 0.85 PTGDR2 (0.36) PTGDR2LMNAMAPTNPSR1ALDH1A1
SCHEMBL2991594 0.84 PTGDR2 (0.39) PTGDR2LMNAMAPTKDM4E
SCHEMBL13093819 0.82 L3MBTL1 (0.42) L3MBTL1TSHRCCNE1CDK2PTGDR2
SCHEMBL1748920 0.82 L3MBTL1 (0.41) L3MBTL1TSHRCCNE1CDK2PTGDR2
SCHEMBL2984531 0.81 DYRK1A (0.34) L3MBTL1TSHRMAPTTDP1SMN1; SMN2
SCHEMBL2989647 0.81 MKNK1 (0.31) PTGDR2KMT2AMEN1
SCHEMBL2996261 0.81 PIM1 (0.34) TSHRPTGDR2LMNAMAPTSMN1; SMN2
SCHEMBL1777936 0.80 MAPT (0.48) L3MBTL1TSHRCCNE1CDK2PTGDR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100256141-A1 NOVEL BIS-AZAINDOLE DERIVATIVES, PREPARATION AND PHARMACEUTICAL USE THEREOF AS KINASE INHIBITORS AVENTIS PHARMA S.A. (FR) 2010-10-07 US disclosed
US-7786114-B2 Bis-azaindole derivatives, preparation and pharmaceutical use thereof as kinase inhibitors AVENTIS PHARMA S.A. (FR) 2010-08-31 US disclosed
US-20080045561-A1 Novel Bis-Azaindole Derivatives, Preparation And Pharmaceutical Use Thereof As Kinase Inhibitors AVENTIS PHARMA S.A. (FR) 2008-02-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080045561-A1 Novel Bis-Azaindole Derivatives, Preparation And Pharmaceutical Use Thereof As Kinase Inhibitors BRSK2, KSR2, CDK2 L3MBTL1 4205/4885TSHR 1091/4885CCNE1 290/4885
US-20100256141-A1 NOVEL BIS-AZAINDOLE DERIVATIVES, PREPARATION AND PHARMACEUTICAL USE THEREOF AS KINASE INHIBITORS BRSK2, KSR2, CDK2 L3MBTL1 4205/4885TSHR 1091/4885CCNE1 290/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.